Read more about the article Recurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy

Recurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy

Background This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and Salivary Gland Cancer, SGC. Among…

Continue ReadingRecurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy
Read more about the article Tremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Tremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

Background Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Tremelimumab is an immunotherapy treatment that helps the…

Continue ReadingTremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Read more about the article Metastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients

Metastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients

Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients with KRAS/RAS-wild type (wt) mCRC…

Continue ReadingMetastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients